Therapy Detail

Therapy Name Afatinib + Nimotuzumab
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Afatinib Gilotrif BIBW 2992 EGFR Inhibitor (Pan) 42 EGFR Inhibitor 2nd gen 3 HER inhibitor (Pan) 6 HER3 Inhibitor 2 Gilotrif (afatinib) is a second-generation pan-Egfr inhibitor with activity against EGFR T790M and EGFR exon 19 and 21 deletions, and also inhibits ERBB2 (HER2), ERBB3 (HER3), ERBB4 (HER4) (PMID: 24435321, PMID: 25505694). Gilotrif (afatinib) is FDA approved for use in non-small cell lung cancer patients harboring non-resistant EGFR mutations, including exon 19 deletions, L858R, S768I, G719X, and L861Q, and for patients with metastatic squamous NSCLC (
Nimotuzumab Theraloc EGFR Antibody 27 Nimotuzumab is a humanized anti-EGFR antibody that blocks EGFR signaling, resulting in anti-tumor activity (PMID: 25842083).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown non-small cell lung carcinoma not applicable Afatinib + Nimotuzumab Phase Ib/II Actionable In a Phase I/II trial, Gilotrif (afatinib) and Nimotuzumab combination treatment resulted in a median progression-free survival of 4.0 months, an overall survival of 11.7 months, and overall response rate of 23% (10/44) in non-small cell lung cancer patients with acquired resistance to Iressa (gefitinib) or Tarceva (erlotinib) (PMID: 26667485). 26667485
Clinical Trial Phase Therapies Title Recruitment Status